$0.15
−1.96%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$0.16
From 52W high−99.59%
Volume5.06M
Market cap$2.17M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$0.16
From 52W high
−99.59%
Volume
5.06M
Market cap
$2.17M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.1x
P/E (TTM)
—
RSI (14)
31.8
MomentumView details →
1D Return
−1.96%
YTD Return
−99.13%
SummaryUpdated Jun 1, 2026
Silexion Therapeutics LTD (NASDAQ:SLXN) is an Israeli biopharmaceutical company founded in 2008 and headquartered in Jerusalem. The company went public in August 2024 and specializes in developing RNA interference (RNAi)-based cancer treatments for solid tumors using its proprietary LODER delivery platform. As a clinical-stage biotechnology company, Silexion focuses on creating targeted therapies that can be delivered directly to tumor sites, representing an innovative approach to cancer treatment that aims to overcome limitations of traditional systemic therapies.
Similar companies
Latest newsMore news →
Silexion Therapeutics Corp. entered definitive agreements for the immediate exercise of outstanding series E warrants to purchase up to 3,216,928 ordinary shares at a reduced exercise price of $0.2603 per share, expecting gross proceeds of about $837,366.36.21d agoSileptai (Shanghai) Biopharmaceutical Technology Co., Ltd. completed a Series A financing of over USD 50 million, led by Decheng Capital, with Huatai GenScript Fund and China Merchants Venture Capital participating, and existing shareholders Morningside Venture Capital, Shunwei Capital, and Qianju Capital continuing to add support.22d ago